Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recently, biologic therapy has become a major advance in the management of moderate-to-severe psoriasis. Although the overall safety profile of biologics is favorable, primary infection or reactivation of latent tuberculosis (TB) is the major concern in the setting of tumor necrosis factor-alpha inhibitor therapy. Therefore, the treatment of latent tuberculosis infection (LTBI) before starting biologics is mandatory to prevent the reactivation of LTBI. A 27-year-old female was treated with adalimumab due to psoriasis. As latent TB was detected by the interferon-γ release assay, we started isoniazid treatment (300 mg/day) 3 weeks before starting adalimumab and maintained this for 6 months. Although the patient’s psoriatic skin lesions improved, after 45 weeks of adalimumab therapy, she visited the emergency department because of fever and back pain for 2 weeks. Abdominopelvic computed tomography (CT) and chest CT revealed multiple nodular lesions on both lungs, peritoneal wall, mesentery, and spleen, along with ascites. In the ascitic fluid, adenosine deaminase was increased to 96.4 U/L, and Mycobacterium tuberculosis grew in an acid-fast bacilli culture. The patient was diagnosed with disseminated TB and treated with conventional TB medication with discontinuation of adalimumab. Five months after the completion of TB treatment, the ustekinumab, an interleukin (IL)-12/IL-23 inhibitor, was administered. Until now, her skin lesions are under excellent control without reactivation of TB for 9 months after starting ustekinumab.
Abstract
Recently, biologic therapy has become a major advance in the management of moderate-to-severe psoriasis. Although the overall safety profile of biologics is favorable, primary infection or reactivation of latent tuberculosis (TB) is the major concern in the setting of tumor necrosis factor-alpha inhibitor therapy. Therefore, the treatment of latent tuberculosis infection (LTBI) before starting biologics is mandatory to prevent the reactivation of LTBI. A 27-year-old female was treated with adalimumab due to psoriasis. As latent TB was detected by the interferon-γ release assay, we started isoniazid treatment (300 mg/day) 3 weeks before starting adalimumab and maintained this for 6 months. Although the patient’s psoriatic skin lesions improved, after 45 weeks of adalimumab therapy, she visited the emergency department because of fever and back pain for 2 weeks. Abdominopelvic computed tomography (CT) and chest CT revealed multiple nodular lesions on both lungs, peritoneal wall, mesentery, and spleen, along with ascites. In the ascitic fluid, adenosine deaminase was increased to 96.4 U/L, and Mycobacterium tuberculosis grew in an acid-fast bacilli culture. The patient was diagnosed with disseminated TB and treated with conventional TB medication with discontinuation of adalimumab. Five months after the completion of TB treatment, the ustekinumab, an interleukin (IL)-12/IL-23 inhibitor, was administered. Until now, her skin lesions are under excellent control without reactivation of TB for 9 months after starting ustekinumab.
참고문헌 (20)
- Carmona L, "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists", Arthritis Rheum, 52, pp.1766~1772 (2005)
- Xie X, "Risk of tuberculosis infection in anti-TNF-α biological therapy : from bench to bedside", J Microbiol Immunol Infect, 47, pp.268~274 (2014)
- Yoo WH, "Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy", Rheumatol Int, 32, pp.787~790 (2012)
- Frieden TR, "Tuberculosis", Lancet, 362, pp.887~899 (2003)
- Toussirot E, "Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review", Recent Pat Inflamm Allergy Drug Discov, 1, pp.39~47 (2007)
- Lynch M, "Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis", JAAD Case Rep, 3, pp.230~232 (2017)
- Guinard E, "Active tuberculosis in psoriasis patients treated with TNF antagonists : a French nationwide retrospective study", J Eur Acad Dermatol Venereol, 30, pp.1336~1341 (2016)
- Amerio P, "Detection and management of latent tuberculosis infections before biologic therapy for psoriasis", J Dermatolog Treat, 24, pp.305~311 (2013)
- 김형우, "Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy", Tuberculosis and Respiratory Diseases, 81(1), pp.6~12 (2018), 대한결핵및호흡기학회
- Handa R, "Tuberculosis and biologics in rheumatology : a special situation", Int J Rheum Dis, 20, pp.1313~1325 (2017)
- Abitbol Y, "Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment : a descriptive study on the GETAID cohort", J Crohns Colitis, 10, pp.1179~1185 (2016)
- Claudia C. Dobler, "Biologic Agents and Tuberculosis", Microbiology Spectrum, 4(6) (2016), American Society for Microbiology[DOI]
- Cantini F, "Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics", Mediators Inflamm, 2017, pp.8909834~ (2017)
- Cantini F, "Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice", Autoimmun Rev, 14, pp.503~509 (2015)
- 이승헌, "Diagnosis and Treatment of Latent Tuberculosis Infection", Tuberculosis and Respiratory Diseases, 78(2), pp.56~63 (2015), 대한결핵및호흡기학회
- Go U, "Tuberculosis prevention and care in Korea: evolution of policy and practice", J Clin Tuberc Other Mycobact Dis, 11, pp.28~36 (2018)
- Winthrop KL, "Tuberculosis associated with therapy against tumor necrosis factor alpha", Arthritis Rheum, 52, pp.2968~2974 (2005)
- Gardam MA, "Anti-tumour necrosis factor agents and tuberculosis risk : mechanisms of action and clinical management", Lancet Infect Dis, 3, pp.148~155 (2003)
- British Thoracic Society Standards of Care Committee, "BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment", Thorax, 60, pp.800~805 (2005)
- Lebwohl M, "From the Medical Board of the National Psoriasis Foundation : monitoring and vaccinations in patients treated with biologics for psoriasis", J Am Acad Dermatol, 58, pp.94~105 (2008)